More than 11% weight loss with experimental drug Eloralintide in early stages of trial
Eli Lilly’s experimental drug Eloralintide helps some patients lose more than 11 percent of their weight in three months without significant side effects, according to a small study published ahead of the American Diabetes Association conference, a milestone in the company’s push into the obesity treatment market.
The study, which was designed to test different doses of the drug, also found that gastrointestinal side effects were minimal, with only about 10 percent of participants experiencing diarrhea and 8 percent experiencing vomiting.
